Curbstone Financial Management Lowered Biotelemetry (Beat) (BEAT) Holding; Xencor (XNCR) Shorts Down By 20.58%

BioTelemetry, Inc. (NASDAQ:BEAT) Logo

Curbstone Financial Management Corp decreased Biotelemetry (Beat) (BEAT) stake by 49.59% reported in 2017Q4 SEC filing. Curbstone Financial Management Corp sold 12,015 shares as Biotelemetry (Beat) (BEAT)’s stock rose 1.79%. The Curbstone Financial Management Corp holds 12,215 shares with $365,000 value, down from 24,230 last quarter. Biotelemetry (Beat) now has $1.11 billion valuation. The stock decreased 3.00% or $1.05 during the last trading session, reaching $33.9. About 179,082 shares traded. BioTelemetry, Inc. (NASDAQ:BEAT) has risen 11.39% since April 20, 2017 and is uptrending. It has underperformed by 0.16% the S&P500.

Xencor Inc (NASDAQ:XNCR) had a decrease of 20.58% in short interest. XNCR’s SI was 2.72M shares in April as released by FINRA. Its down 20.58% from 3.42M shares previously. With 793,600 avg volume, 3 days are for Xencor Inc (NASDAQ:XNCR)’s short sellers to cover XNCR’s short positions. The SI to Xencor Inc’s float is 6.99%. The stock decreased 2.56% or $0.78 during the last trading session, reaching $29.7. About 107,096 shares traded. Xencor, Inc. (NASDAQ:XNCR) has risen 17.37% since April 20, 2017 and is uptrending. It has outperformed by 5.82% the S&P500.

Investors sentiment decreased to 0.88 in Q4 2017. Its down 0.40, from 1.28 in 2017Q3. It dived, as 47 investors sold BEAT shares while 57 reduced holdings. 27 funds opened positions while 65 raised stakes. 27.71 million shares or 8.71% more from 25.49 million shares in 2017Q3 were reported. Gamco Invsts Incorporated Et Al accumulated 24,628 shares. State Of Alaska Department Of Revenue holds 0% of its portfolio in BioTelemetry, Inc. (NASDAQ:BEAT) for 6,128 shares. Hodges Cap Management holds 318,990 shares. Group Inc owns 25,139 shares. California Employees Retirement has invested 0% in BioTelemetry, Inc. (NASDAQ:BEAT). Ameritas Inv Inc invested in 2,654 shares or 0% of the stock. Alliancebernstein Ltd Partnership reported 37,500 shares stake. Voya Invest Mgmt Ltd Liability owns 12,980 shares. Bnp Paribas Arbitrage holds 0% in BioTelemetry, Inc. (NASDAQ:BEAT) or 12,863 shares. Envestnet Asset Management Inc, Illinois-based fund reported 19,862 shares. Stevens First Principles Inv has 0% invested in BioTelemetry, Inc. (NASDAQ:BEAT) for 120 shares. Riverhead Capital Management Limited Liability Corporation invested 0% of its portfolio in BioTelemetry, Inc. (NASDAQ:BEAT). Texas Permanent School Fund owns 20,781 shares for 0.01% of their portfolio. Swiss Retail Bank holds 0% of its portfolio in BioTelemetry, Inc. (NASDAQ:BEAT) for 50,800 shares. 500 are owned by Advisory Service Limited Liability Corp.

Among 6 analysts covering BioTelemetry (NASDAQ:BEAT), 6 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. BioTelemetry has $41 highest and $20 lowest target. $38.80’s average target is 14.45% above currents $33.9 stock price. BioTelemetry had 10 analyst reports since July 28, 2015 according to SRatingsIntel. Dougherty & Company initiated it with “Buy” rating and $26 target in Friday, December 2 report. Dougherty maintained BioTelemetry, Inc. (NASDAQ:BEAT) on Friday, February 23 with “Buy” rating. The stock has “Buy” rating by Sidoti on Tuesday, September 13. Raymond James maintained BioTelemetry, Inc. (NASDAQ:BEAT) on Thursday, November 30 with “Buy” rating. Dougherty & Company maintained BioTelemetry, Inc. (NASDAQ:BEAT) on Tuesday, July 28 with “Buy” rating. Dougherty & Company maintained BioTelemetry, Inc. (NASDAQ:BEAT) on Tuesday, April 11 with “Buy” rating.

Analysts await BioTelemetry, Inc. (NASDAQ:BEAT) to report earnings on May, 2. They expect $0.25 EPS, up 56.25% or $0.09 from last year’s $0.16 per share. BEAT’s profit will be $8.18 million for 33.90 P/E if the $0.25 EPS becomes a reality. After $0.32 actual EPS reported by BioTelemetry, Inc. for the previous quarter, Wall Street now forecasts -21.88% negative EPS growth.

Since October 25, 2017, it had 2 insider buys, and 6 selling transactions for $146,630 activity. $125,050 worth of Xencor, Inc. (NASDAQ:XNCR) was sold by Foster Paul A. 20,000 shares were sold by Baracchini Edgardo Jr, worth $592,848. STAFFORD JOHN S III bought 150,000 shares worth $2.97 million.

Among 8 analysts covering Xencor (NASDAQ:XNCR), 6 have Buy rating, 0 Sell and 2 Hold. Therefore 75% are positive. Xencor has $4600 highest and $18 lowest target. $35.86’s average target is 20.74% above currents $29.7 stock price. Xencor had 21 analyst reports since August 5, 2015 according to SRatingsIntel. On Monday, March 19 the stock rating was maintained by Wedbush with “Outperform”. The stock of Xencor, Inc. (NASDAQ:XNCR) earned “Buy” rating by Cantor Fitzgerald on Wednesday, February 28. Leerink Swann initiated the shares of XNCR in report on Wednesday, March 28 with “Buy” rating. The firm earned “Hold” rating on Saturday, August 8 by Zacks. Piper Jaffray maintained Xencor, Inc. (NASDAQ:XNCR) on Thursday, March 15 with “Buy” rating. Cantor Fitzgerald initiated Xencor, Inc. (NASDAQ:XNCR) rating on Thursday, February 22. Cantor Fitzgerald has “Buy” rating and $33.0 target. Piper Jaffray maintained the shares of XNCR in report on Sunday, November 12 with “Buy” rating. Leerink Swann maintained the stock with “Outperform” rating in Thursday, September 17 report. The firm has “Buy” rating by Canaccord Genuity given on Monday, November 13. Canaccord Genuity initiated the shares of XNCR in report on Tuesday, December 22 with “Buy” rating.

Investors sentiment increased to 1.21 in 2017 Q4. Its up 0.31, from 0.9 in 2017Q3. It improved, as 15 investors sold Xencor, Inc. shares while 28 reduced holdings. 15 funds opened positions while 37 raised stakes. 36.52 million shares or 1.10% more from 36.12 million shares in 2017Q3 were reported. Victory Cap Mgmt reported 33,954 shares. The Missouri-based Piermont Capital Inc has invested 0.07% in Xencor, Inc. (NASDAQ:XNCR). Millennium Management Limited Liability Company holds 0% or 66,434 shares in its portfolio. Great West Life Assurance Com Can reported 6,526 shares or 0% of all its holdings. Price T Rowe Assoc Incorporated Md stated it has 5.09M shares or 0.02% of all its holdings. 22,173 are held by Wells Fargo And Company Mn. Schwab Charles Investment Mngmt has invested 0% of its portfolio in Xencor, Inc. (NASDAQ:XNCR). Primecap Management Com Ca stated it has 6.16 million shares. Credit Suisse Ag owns 0% invested in Xencor, Inc. (NASDAQ:XNCR) for 46,135 shares. State Of Wisconsin Board stated it has 0% of its portfolio in Xencor, Inc. (NASDAQ:XNCR). Public Employees Retirement Association Of Colorado holds 0% of its portfolio in Xencor, Inc. (NASDAQ:XNCR) for 2,674 shares. The New York-based Cannell Peter B Inc has invested 0.17% in Xencor, Inc. (NASDAQ:XNCR). Swiss Fincl Bank owns 66,400 shares for 0% of their portfolio. The California-based Falcon Point Limited Com has invested 0.06% in Xencor, Inc. (NASDAQ:XNCR). Northern Tru Corporation has invested 0% of its portfolio in Xencor, Inc. (NASDAQ:XNCR).

Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on discovery and development of engineered monoclonal antibodies to treat severe and life-threatening diseases with unmet medical needs. The company has market cap of $1.61 billion. It develops its antibody product candidates to treat autoimmune and allergic diseases, cancer, and other conditions. It currently has negative earnings. The companyÂ’s product candidates include XmAb5871, an immune inhibitor, which is in Phase II clinical trials for the treatment of autoimmune diseases; XmAb7195, an immune inhibitor that is in Phase I clinical for use in treating asthma and allergic diseases; XmAb14045, a bispecific oncology candidate, which is in phase I clinical trials for the treatment of acute myeloid leukemia; and XmAb13676 that is in phase I clinical trials for the treatment of B-cell malignancies.

Xencor, Inc. (NASDAQ:XNCR) Institutional Positions Chart